Anti–IL-6 and JAK Inhibitors for Severe Neurologic Toxicity of Checkpoint Inhibitors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Anti–Interleukin-6 and Janus Kinase Inhibitors for Severe Neurologic Toxicity of Checkpoint Inhibitors
Neurol Neuroimmunol Neuroinflamm 2021 Nov 01;[EPub Ahead of Print], A Picca, N Valyraki, C Birzu, N Kramkimel, O Hermine, N Zahr, G Berzero, D PsimarasFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.